Issue 14, 2018

An enzymatic advance in nicotine cessation therapy

Abstract

A nicotine-degrading enzyme termed NicA2 was altered (NicA2-J1) through fusion of an albumin binding domain to increase its half-life. Examination of NicA2-J1 in vivo demonstrated a complete blockade of brain nicotine access, which in turn blunted nicotine's psychoactive effects. These data further support development of pharmacokinetic nicotine cessation therapeutics.

Graphical abstract: An enzymatic advance in nicotine cessation therapy

Supplementary files

Article information

Article type
Communication
Submitted
28 Nov 2017
Accepted
28 Dec 2017
First published
02 Jan 2018

Chem. Commun., 2018,54, 1686-1689

An enzymatic advance in nicotine cessation therapy

S. Xue, M. Kallupi, B. Zhou, L. C. Smith, P. O. Miranda, O. George and K. D. Janda, Chem. Commun., 2018, 54, 1686 DOI: 10.1039/C7CC09134F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements